Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Bioxytran Inc

Company price
0.0209 USD -0.00 ( 15.38%)
Last update at 2026-11-19T18:48:00Z
VOLUME
20100
Market Cap
4.12M

Momentum Score

…

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.03
High
52 Week Price Range
0.03
Low
0.17
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Bioxytran Inc (BIXT) is limited; filings describe it as a development-stage life sciences company. Long-term growth could depend on advancement of its research and regulatory progress, and securing financing or partnerships, which may attract investors seeking early-stage biotech exposure.

Key risks include limited disclosure, no established revenue, reliance on external funding with dilution risk, development and regulatory uncertainty, and low liquidity on the OTCQB.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
0.74M
ROCE
71.55%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.12M -2.38M -4.56M -2.66M -4.53M
Minority interest 0.00M 0.01M 0.09M 0.19M 0.50M
Net income -2.12M -2.37M -4.47M -2.46M -4.03M
Selling general administrative 1.39M 2.11M 2.65M 1.16M 2.20M
Reconciled depreciation 0.01M 0.01M 0.01M 0.00M -
Ebit - - - - -4.21M
Ebitda - - - -2.13M -4.21M
Operating income -1.85M -2.23M -3.81M -2.14M -4.21M
Interest expense 0.19M 0.77M 0.54M 0.52M 0.31M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.19M -0.77M -0.54M -0.52M -0.31M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.85M 2.23M 3.81M 2.14M 4.21M
Total other income expense net -0.08M 0.62M -0.21M - -
Net income from continuing ops -2.12M -2.38M -4.56M -2.66M -4.53M
Net income applicable to common shares - - - - -4.03M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.66M 0.14M 0.14M 0.37M 0.12M
Intangible assets 0.15M 0.13M 0.11M 0.08M 0.05M
Total liab 3.25M 1.93M 3.25M 3.66M 3.28M
Total stockholder equity -2.59M -1.79M -2.43M -2.70M -2.76M
Other current liab 0.50M 0.41M 1.03M 0.04M 0.11M
Common stock - - - - 0.11M
Capital stock 0.15M 0.13M 0.15M 0.12M 0.11M
Retained earnings -21.04M -18.92M -15.50M -11.22M -8.75M
Cash 0.51M 0.01M 0.03M 0.30M 0.07M
Total current liabilities 3.25M 1.93M 3.25M 3.66M 3.28M
Net debt 0.74M 1.09M 1.90M 1.87M 2.05M
Short long term debt 1.25M 1.09M 1.93M 2.17M 2.12M
Total current assets 0.51M 0.01M 0.03M 0.30M 0.07M
Net tangible assets - - - - -2.81M
Accounts payable 0.00M 0.00M 0.00M 0.00M 0.53M
Non current assets total 0.15M 0.13M 0.11M 0.08M 0.05M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.03M -0.04M -0.03M -0.04M
Change to liabilities - - - - 1.90M
Total cashflows from investing activities - - - - -0.04M
Net borrowings 0.32M 0.33M 0.00M - 1.17M
Total cash from financing activities 1.05M 0.06M 0.55M 2.06M 1.76M
Change to operating activities - - - - 0.27M
Net income -2.12M -2.37M -4.47M -2.46M -4.03M
Change in cash 0.50M -0.02M -0.27M 0.22M 0.03M
Begin period cash flow 0.01M 0.03M 0.30M 0.07M 0.04M
End period cash flow 0.51M 0.01M 0.03M 0.30M 0.07M
Total cash from operating activities -0.53M -0.06M -0.78M -1.81M -1.70M
Issuance of capital stock 0.44M 0.06M 0.55M 0.68M 0.60M
Depreciation 0.01M 0.01M 0.01M 0.00M -
Other cashflows from financing activities - - - - 0.60M
Change to netincome - - - - 0.09M
Capital expenditures 0.02M 0.03M 0.04M 0.03M 0.04M
Change in working capital 0.99M 1.23M 3.20M 0.30M 2.17M
Stock based compensation 0.38M 0.63M 0.18M 0.18M 0.58M
Other non cash items - 0.84M 0.40M 0.37M 0.08M
Free cash flow -0.55M -0.08M -0.82M -1.84M -1.73M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BIXT
Bioxytran Inc
-0.00
15.38%
0.02 - - 532.56 77.85 706.64 -5.72
NVO
Novo Nordisk A/S
-0.54
1.36%
38.90 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
520.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
2.34
0.25%
923.34 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Bioxytran Inc

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

75 2nd Avenue, Needham, MA, United States, 02494

617 454 1199

Name Title Year Born
Dr. David Platt Ph.D. Chairman, CEO & Pres 1953
Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, CMA, CPA, M.B.A. CFO, Treasurer & Sec. 1962
Mr. Michael Sheikh B.S. Exec. VP of Bus. Devel. 1970
Dr. David Platt Ph.D. Chairman, CEO & President 1953
Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, CMA, CPA, M.B.A. CFO, Treasurer & Secretary 1962
Mr. Michael Sheikh B.S. Chief Communication Officer 1970
Dr. David Platt Ph.D. Chairman, CEO, President & Secretary 1953
Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, M.B.A. CFO & Treasurer 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…